A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Clinical trial NCT02078960 · TERMINATED
Trial details
- NCT number
- NCT02078960
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-09
- Primary completion
- 2017-07-06
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.